Literature DB >> 20555028

Developmental programming: insulin sensitizer treatment improves reproductive function in prenatal testosterone-treated female sheep.

Almudena Veiga-Lopez1, James S Lee, Vasantha Padmanabhan.   

Abstract

Prenatal testosterone (T) excess causes reproductive and metabolic disruptions including insulin resistance, attributes of women with polycystic ovary syndrome. This study tested the hypothesis that insulin resistance contributes toward severity of reproductive disruptions in prenatally T-treated females. Pregnant sheep were injected im with 100 mg of T-propionate semiweekly from d 30-90 of gestation. Immediately after the first breeding season, a subset of controls and prenatal T-treated (TR) sheep were administered an insulin sensitizer (rosiglitazone; 8 mg/d) orally for 8 months. Untreated control and prenatal T-treated females (T group) were studied in parallel. Biochemical analyses revealed rosiglitazone to be safe for use in sheep. Glucose tolerance tests performed before and after the insulin sensitizer treatment found that insulin sensitizer decreased cumulative insulin, cumulative insulin/glucose ratio, and insulin area under the curve by about 50% and increased the insulin sensitivity index by about 70% in the TR compared with the T group. Twenty percent of TR females showed a reduced number of cycles in the second relative to first breeding season as opposed to 80% of T group females showing such deterioration. Insulin sensitizer treatment also decreased the number of aberrant cycles (>/=18 d) during the second breeding season in the TR group relative to the first as opposed to the T group females showing an increase in the second breeding season relative to the first. These findings provide evidence that insulin sensitizer treatment prevents further deterioration of the reproductive axis in prenatal T-treated sheep, a finding of translational relevance to women with polycystic ovary syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20555028      PMCID: PMC2940534          DOI: 10.1210/en.2010-0124

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  67 in total

1.  Rosiglitazone (Avandia): hepatic, cardiac and hematological reactions.

Authors:  M McMorran; D Vu
Journal:  CMAJ       Date:  2001-07-10       Impact factor: 8.262

2.  In utero exposure of female lambs to testosterone reduces the sensitivity of the gonadotropin-releasing hormone neuronal network to inhibition by progesterone.

Authors:  J E Robinson; R A Forsdike; J A Taylor
Journal:  Endocrinology       Date:  1999-12       Impact factor: 4.736

3.  Fetal programming: excess prenatal testosterone reduces postnatal luteinizing hormone, but not follicle-stimulating hormone responsiveness, to estradiol negative feedback in the female.

Authors:  Hirendra N Sarma; Mohan Manikkam; Carol Herkimer; James Dell'Orco; Kathleen B Welch; Douglas L Foster; Vasantha Padmanabhan
Journal:  Endocrinology       Date:  2005-06-23       Impact factor: 4.736

4.  Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.

Authors:  Harold E Lebovitz; Margaret Kreider; Martin I Freed
Journal:  Diabetes Care       Date:  2002-05       Impact factor: 19.112

5.  Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.

Authors:  Jean-Patrice Baillargeon; Daniela J Jakubowicz; Maria J Iuorno; Salomon Jakubowicz; John E Nestler
Journal:  Fertil Steril       Date:  2004-10       Impact factor: 7.329

6.  A prospective randomized trial comparing the clinical and endocrinological outcome with rosiglitazone versus laparoscopic ovarian drilling in patients with polycystic ovarian disease resistant to ovulation induction with clomiphene citrate.

Authors:  K K Roy; Jinee Baruah; Aparna Sharma; J B Sharma; Sunesh Kumar; Garima Kachava; Debjyoti Karmakar
Journal:  Arch Gynecol Obstet       Date:  2009-12-03       Impact factor: 2.344

7.  Case series of liver failure associated with rosiglitazone and pioglitazone.

Authors:  James S Floyd; Elizabeth Barbehenn; Peter Lurie; Sidney M Wolfe
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-12       Impact factor: 2.890

8.  Hyperandrogenism and hyperinsulinism in children of women with polycystic ovary syndrome: a controlled study.

Authors:  Sarah C Kent; Carol L Gnatuk; Allen R Kunselman; Laurence M Demers; Peter A Lee; Richard S Legro
Journal:  J Clin Endocrinol Metab       Date:  2008-02-12       Impact factor: 5.958

Review 9.  Sexual differentiation of reproductive neuroendocrine function in sheep.

Authors:  R I Wood; D L Foster
Journal:  Rev Reprod       Date:  1998-05

10.  Disturbed stress responses in women with polycystic ovary syndrome.

Authors:  S Benson; P C Arck; S Tan; S Hahn; K Mann; N Rifaie; O E Janssen; M Schedlowski; S Elsenbruch
Journal:  Psychoneuroendocrinology       Date:  2009-01-15       Impact factor: 4.905

View more
  22 in total

1.  Developmental programming: prenatal and postnatal contribution of androgens and insulin in the reprogramming of estradiol positive feedback disruptions in prenatal testosterone-treated sheep.

Authors:  Bachir Abi Salloum; Carol Herkimer; James S Lee; Almudena Veiga-Lopez; Vasantha Padmanabhan
Journal:  Endocrinology       Date:  2012-03-27       Impact factor: 4.736

Review 2.  Steroidogenic versus Metabolic Programming of Reproductive Neuroendocrine, Ovarian and Metabolic Dysfunctions.

Authors:  Rodolfo C Cardoso; Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  Neuroendocrinology       Date:  2015-04-01       Impact factor: 4.914

Review 3.  Hyperandrogenic origins of polycystic ovary syndrome - implications for pathophysiology and therapy.

Authors:  David H Abbott; Daniel A Dumesic; Jon E Levine
Journal:  Expert Rev Endocrinol Metab       Date:  2019-02-15

4.  Developmental programing: impact of testosterone on placental differentiation.

Authors:  E M Beckett; O Astapova; T L Steckler; A Veiga-Lopez; V Padmanabhan
Journal:  Reproduction       Date:  2014-05-19       Impact factor: 3.906

Review 5.  Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome.

Authors:  Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  J Mol Endocrinol       Date:  2018-10-16       Impact factor: 5.098

6.  Developmental Programming: Impact of Gestational Steroid and Metabolic Milieus on Mediators of Insulin Sensitivity in Prenatal Testosterone-Treated Female Sheep.

Authors:  Muraly Puttabyatappa; Victoria Andriessen; Makeda Mesquitta; Lixia Zeng; Subramaniam Pennathur; Vasantha Padmanabhan
Journal:  Endocrinology       Date:  2017-09-01       Impact factor: 4.736

7.  Developmental Programming: Insulin Sensitizer Prevents the GnRH-Stimulated LH Hypersecretion in a Sheep Model of PCOS.

Authors:  Rodolfo C Cardoso; Ashleigh Burns; Jacob Moeller; Donal C Skinner; Vasantha Padmanabhan
Journal:  Endocrinology       Date:  2016-10-28       Impact factor: 4.736

Review 8.  Developmental origin of reproductive and metabolic dysfunctions: androgenic versus estrogenic reprogramming.

Authors:  Vasantha Padmanabhan; Almudena Veiga-Lopez
Journal:  Semin Reprod Med       Date:  2011-06-27       Impact factor: 1.303

9.  Developmental Programming: Prenatal and Postnatal Androgen Antagonist and Insulin Sensitizer Interventions Prevent Advancement of Puberty and Improve LH Surge Dynamics in Prenatal Testosterone-Treated Sheep.

Authors:  Vasantha Padmanabhan; Almudena Veiga-Lopez; Carol Herkimer; Bachir Abi Salloum; Jacob Moeller; Evan Beckett; Rohit Sreedharan
Journal:  Endocrinology       Date:  2015-04-28       Impact factor: 4.736

10.  Developmental Programming: Impact of Gestational Steroid and Metabolic Milieus on Adiposity and Insulin Sensitivity in Prenatal Testosterone-Treated Female Sheep.

Authors:  Rodolfo C Cardoso; Almudena Veiga-Lopez; Jacob Moeller; Evan Beckett; Anthony Pease; Erica Keller; Vanessa Madrigal; Gregorio Chazenbalk; Daniel Dumesic; Vasantha Padmanabhan
Journal:  Endocrinology       Date:  2015-12-09       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.